Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its recent all-time high of $808. The company initially aimed to acquire $200 million in BNB but is now raising up to $520 million through a $500 million equity line of credit and a $20 million stock purchase agreement. Windtree plans to partner with crypto exchange Kraken for asset custody. This investment strategy mirrors trends seen in other publicly traded companies diversifying their portfolios with digital assets. Windtree’s stock has fluctuated, dropping about 5% recently but up 162% in the last month. The growing trend of companies building crypto treasuries continues to be notable, with firms like Nano Labs also committing substantial resources to BNB purchases.

Source 🔗